Form 4: Vaxart CMO Reports Routine Stock Transaction

Vaxart's Chief Medical Officer, James F. Cummings, reported a disposition of shares to cover tax obligations related to vested restricted stock units.

Summary

• James F. Cummings, Chief Medical Officer of Vaxart, Inc. (VXRT), reported a transaction on February 2, 2026.
• 7,965 shares of Common Stock were disposed of at a price of $0.6085 per share.
• This disposition represents shares withheld by Vaxart to satisfy income tax withholding and remittance obligations for net-settled Restricted Stock Units (RSUs) that vested on February 2, 2026.
• Following this transaction, Mr. Cummings beneficially owns 737,792 shares of Vaxart Common Stock.
• The total beneficially owned shares include 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction for tax purposes, which is neutral in sentiment, balanced by the positive of ESPP acquisition.

Positives

• The reporting person acquired 75,618 shares under the Vaxart, Inc. 2022 Employee Stock Purchase Plan, indicating continued investment in the company.

Negatives

• 7,965 shares were disposed of to cover income tax withholding obligations related to vested Restricted Stock Units.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those for tax purposes related to RSU vesting, are common and generally do not reflect a change in management's long-term view of the company's operational performance or strategic direction. The acquisition of shares via an Employee Stock Purchase Plan is also a routine benefit.

Stakeholder Impact

• Shareholders: Provides transparency on insider holdings and routine compensation-related share movements, which is standard for public companies.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the disposition of shares to cover tax obligations from vested RSUs, alongside an acquisition through an ESPP. Such transactions are common and do not typically signal a change in the company's fundamental prospects or management's long-term view, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Vaxart, VXRT, Form 4, insider transaction, stock, RSU, Chief Medical Officer, James F. Cummings, employee stock purchase plan